zelicapavir LOTUS is an Enanta Pharmaceuticals Inc program in RSV (pediatric). Its next catalyst is a Readout in Q1 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: RSV (pediatric). Sponsor: Enanta Pharmaceuticals Inc (ENTA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for zelicapavir LOTUS is a Readout in Q1 2027.
No FDA decision for zelicapavir LOTUS is in our archive yet.
In our records zelicapavir LOTUS is under review or in development for RSV (pediatric).
Enanta Pharmaceuticals Inc (ENTA).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.